Anti-GPCR GPR17 antibody [EPR26422-118],Abcam,AB314307
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human, Mouse, Rat
Application
ICC/IF, IHC-P, mIHC, IP
Platform ID
BAB134745849

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Product Specifications
Scientific Background
Specifications
NameAnti-GPCR GPR17 antibody [EPR26422-118]
Cat. No.AB314307
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ApplicationICC/IF, IHC-P, mIHC, IP
ClonalityMonoclonal
Clone NumberEPR26422-118
Concentration0.517 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only
Scientific Background
Target data Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia. See full target information GPR17
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
